alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUL-31-1998
<PERIOD-END>                               JAN-31-1998
<CASH>                                        $668,000
<SECURITIES>                                  $795,000
<RECEIVABLES>                               $2,528,000
<ALLOWANCES>                                         0
<INVENTORY>                                 $2,216,000
<CURRENT-ASSETS>                            $6,213,000
<PP&E>                                        $922,000
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                             $10,420,000
<CURRENT-LIABILITIES>                       $2,046,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       $56,000
<OTHER-SE>                                  $8,306,000
<TOTAL-LIABILITY-AND-EQUITY>               $10,420,000
<SALES>                                     $3,867,000
<TOTAL-REVENUES>                            $3,867,000
<CGS>                                       $2,021,000
<TOTAL-COSTS>                               $2,021,000
<OTHER-EXPENSES>                            $1,188,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             $15,000
<INCOME-PRETAX>                             $3,323,000
<INCOME-TAX>                                   $65,000
<INCOME-CONTINUING>                           $479,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  $479,000
<EPS-PRIMARY>                                      .43
<EPS-DILUTED>                                      .43


        

</TABLE>
## Breadcrumb

-  Home 
-  News & Events 
-  Grantee News 

# 2018 Grantee News Items

                - Smelling in tiny houses: How ciliary electric currents keep olfaction reliable Monell Center  (12/31/2018)
                - UW professor leads research team on olfactory sensory receptors in mice University of Wyoming  (12/14/2018)
                - To detect new odors, fruit fly brains improve on a well-known computer algorithm University of California, San Diego, and Salk Institute  (12/03/2018)
                - Epigenetic map may pave way for new therapeutic solutions to hearing loss Tel Aviv University  (12/03/2018)
                - UMSOM expert discovers key gene in cells associated with age-related hearing loss University of Maryland School of Medicine  (11/21/2018)
                - Brain-computer interface enables people with paralysis to control tablet devices Brown University via EurekAlert!  (11/21/2018)
                - Appendix linked to toxic Parkinson’s protein Van Andel Research Institute  (11/20/2018)
                - Researchers hope a "robo-nose"could give K-9 officers a break: Animal stem cells grown into a preliminary device to detect bombs and drugs Duke School of Medicine  (11/19/2018)
                - Patients with untreated hearing loss incur higher health care costs over time Johns Hopkins Bloomberg School of Public Health  (11/08/2018)
                - Strong ability to detect and perceive motion may prevent pilot disorientation Massachusetts Eye and Ear  (10/31/2018)
                - "Navigator" neurons play critical role in sense of smell Stowers Institute for Medical Research  (10/26/2018)
                - Study points to possible new therapy for hearing loss University of Rochester Medical Center  (10/15/2018)
                - Discovery of inner ear function may improve diagnosis of hearing impairment Linköping University   (10/10/2018)
                - Infants capable of complex babble may grow into stronger readers: Some skills needed for literacy may be developed in infancy Florida State University  (10/10/2018)
                - What’s that smell? Neuroscientists are figuring it out Cold Spring Harbor Laboratory  (10/02/2018)

#### Pagination

-                Current page            1 
-                Page            2 
-                Page            3 
- …
-  Next page›› 
-  Last pageLast » 

## Media Inquiries

Contact the NIDCD press office at news@nidcd.nih.gov.

## Grantee News Archive

              - 2024 
              - 2023 
              - 2022 
              - 2021 
              - 2020 
              - 2019 
              - 2018 
              - 2017 
              - 2016 
              - 2015 
              - 2014 
              - 2013
Exhibit 10.6

CLIENT LICENSE AGREEMENT AMENDMENT

Re: License Agreement, dated as of 04/25/2011,
by and between Immuno Cellular Therapeutics, as Client and Regent Business Centers Woodland Hills, LLC, as Licensor.

The above referenced
Agreement is hereby amended subject to the following modifications or revisions:



| | 1. | The term set forth in the Agreement is hereby extended. The renewal term will commence on 07/01/2011 and will expire on 06/30/2012.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------



| | 2. | The Fixed Monthly Office Fee for the Office #3093/94/95 shall be $3,493.00 subject to any modifications and/or revisions, which may be agreed to by both
Regent and Client.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 3. | The contents of the Office as set forth in the License Agreement are changed. The fee for three Basic Service Packages shall be $545.00 per month. The fee
for the four internet connect shall be $100.00 per month.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 4. | Refundable Retainer in the amount of $200.00 is required.
| | -- | ---------------------------------------------------------

All capitalized terms used in this Agreement shall have the same meaning as set forth in and defined in the License Agreement.

Except as set forth herein, all other terms and conditions of the License Agreement shall remain in full force and effect.

Agreed to:

Dated: June 14, 2011



|                                             |  |                                
|-------------------------------------------- |  | -------------------------------
|Immuno Cellular Therapeutics                
|                                             | 
|By:                                          |  | /s/ Manish Singh               
|                                             | 
|Name:                                        |  | Manish Singh                   
|                                            
|Regent Business Centers Woodland Hills, LLC.
|                                             | 
|By:                                          |  | /s/ Kristin Miller             
|                                             | 
|Name:                                        |  | Kristin Miller, General Manager
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                                      <C>
<PERIOD-TYPE>                              3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                      95,044,345
<SECURITIES>                                         0
<RECEIVABLES>                                  568,156
<ALLOWANCES>                                  (26,884)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      46,919,590
<DEPRECIATION>                            (25,081,238)
<TOTAL-ASSETS>                             140,122,062
<CURRENT-LIABILITIES>                       95,902,391
<BONDS>                                     15,974,535
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  28,245,136
<TOTAL-LIABILITY-AND-EQUITY>               140,122,062
<SALES>                                              0
<TOTAL-REVENUES>                            10,536,074
<CGS>                                                0
<TOTAL-COSTS>                               10,792,242
<OTHER-EXPENSES>                          (81,877,308)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             971,605
<INCOME-PRETAX>                             58,632,748
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         58,632,748
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                58,632,748
<EPS-PRIMARY>                                   221.48
<EPS-DILUTED>                                   221.48
        

</TABLE>
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. Con. Res. 100 Introduced in Senate (IS)]

109th CONGRESS
  2d Session
S. CON. RES. 100

     Expressing the sense of Congress that an artistic tribute to 
    commemorate the speech given by President Ronald Reagan at the 
 Brandenburg Gate on June 12, 1987, should be placed within the United 
                            States Capitol.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             June 12, 2006

  Mr. Allard submitted the following concurrent resolution; which was 
         referred to the Committee on Rules and Administration

_______________________________________________________________________

                         CONCURRENT RESOLUTION

 
     Expressing the sense of Congress that an artistic tribute to 
    commemorate the speech given by President Ronald Reagan at the 
 Brandenburg Gate on June 12, 1987, should be placed within the United 
                            States Capitol.

Whereas the people of the United States successfully defended freedom and 
        democracy for over 40 years in a global Cold War against an aggressive 
        Communist tyranny;
Whereas President Ronald Wilson Reagan's demonstration of unwavering personal 
        conviction during this conflict served to inspire millions of people 
        throughout the United States and around the world to seek democracy, 
        freedom, and greater individual liberty; and
Whereas Ronald Wilson Reagan's determined stand against the Soviet empire during 
        his eight years as President served as the catalyst for the end of that 
        regime: Now, therefore, be it
    Resolved by the Senate (the House of Representatives concurring), 
That it is the sense of Congress that an artistic tribute to 
commemorate the speech given by President Ronald Reagan at the 
Brandenburg Gate on June 12, 1987, during which he uttered the immortal 
lines ``Mr. Gorbachev, tear down this wall!'', should be placed within 
the United States Capitol.
                                 <all>
```
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<CIK> 0000892449
<NAME> FIRST COMMUNITY FINANCIAL GROUP
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                           11620
<INT-BEARING-DEPOSITS>                            5648
<FED-FUNDS-SOLD>                                  1000
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                      41658
<INVESTMENTS-CARRYING>                             959
<INVESTMENTS-MARKET>                              1024
<LOANS>                                         199165
<ALLOWANCE>                                       2122
<TOTAL-ASSETS>                                  294474
<DEPOSITS>                                      263121
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                               1370
<LONG-TERM>                                       3818
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                          4988
<OTHER-SE>                                       21177
<TOTAL-LIABILITIES-AND-EQUITY>                  294474
<INTEREST-LOAN>                                  18821
<INTEREST-INVEST>                                 1503
<INTEREST-OTHER>                                   836
<INTEREST-TOTAL>                                 21160
<INTEREST-DEPOSIT>                                7884
<INTEREST-EXPENSE>                                8039
<INTEREST-INCOME-NET>                            13121
<LOAN-LOSSES>                                     1015
<SECURITIES-GAINS>                                   6
<EXPENSE-OTHER>                                  15883
<INCOME-PRETAX>                                    486
<INCOME-PRE-EXTRAORDINARY>                         486
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       719
<EPS-PRIMARY>                                      .38
<EPS-DILUTED>                                      .36
<YIELD-ACTUAL>                                    9.64
<LOANS-NON>                                       4381
<LOANS-PAST>                                       319
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                  1420
<CHARGE-OFFS>                                      807
<RECOVERIES>                                        25
<ALLOWANCE-CLOSE>                                 2122
<ALLOWANCE-DOMESTIC>                              2122
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
<PAGE>   1
EXHIBIT 11.1

                         Ribozyme Pharmaceuticals, Inc.
                       Computation of Net Loss Per Share





<TABLE>
<CAPTION>
                                                                              Twelve Months   Twelve Months
                                                                                 ending          ending
                                                                                12/31/96        12/31/95
                                                                              ------------    ------------
<S>                                                                           <C>             <C>
Weighted average common shares
  outstanding .............................................................      5,165,717         981,671

Net effect of dilutive common stock
  options and warrants pursuant to
  Staff Accounting Bulletin No. 83 ........................................         24,969          99,877

Assumed conversion of preferred stock
  from original date of issuance,
  pursuant to staff policy ................................................        654,301       2,148,793

                                                                              ------------    ------------

  Total ...................................................................      5,844,987       3,230,341


  Net loss ................................................................   $(15,267,580)   $(12,480,147)
                                                                              ============    ============

  Net loss per share ......................................................   $      (2.61)   $      (3.86)
                                                                              ============    ============
</TABLE>
#### S.M. Pires, Appellant, v Frota Oceanica Brasileira, S.A., Respondent, et al., Defendants.

Submitted January 3, 2011;

decided February 15, 2011

Motion for leave to appeal dismissed upon the ground that the order sought to be appealed from does not finally determine the action within the meaning of the Constitution.
IV 

109TH CONGRESS 

1ST SESSION S. CON. RES. 39 

IN THE HOUSE OF REPRESENTATIVES 

JULY 29, 2005 

Referred to the Committee on Armed Services 

CONCURRENT RESOLUTION 

To express the sense of Congress on the Purple Heart. 

Whereas the Purple Heart is the oldest military decoration in 

the world in present use; 

Whereas the Purple Heart is awarded in the name of the 

President of the United States to members of the Armed 

Forces who are wounded in conflict with an enemy force 

or are wounded while held by an enemy force as prisoners 

of war, and posthumously to the next of kin of members 

of the Armed Forces who are killed in conflict with an 

enemy force or who die of a wound received in conflict 

with an enemy force; 

Whereas the Purple Heart was established on August 7, 

1782, during the Revolutionary War, when General 

George Washington issued an order establishing the Honorary Badge of Distinction, otherwise known as the 

Badge of Military Merit; 
2 

SCON 39 RFH 

Whereas the award of the Purple Heart ceased with the end 

of the Revolutionary War, but was revived in 1932, the 

200th anniversary of George Washington’s birth, out of 

respect for his memory and military achievements; and 

Whereas National Purple Heart Recognition Day is a fitting 

tribute to George Washington and to the more than 

1,535,000 recipients of the Purple Heart, approximately 

550,000 of whom are still living: Now, therefore, be it 

1 Resolved by the Senate (the House of Representatives 

2 concurring), That Congress— 

3 (1) supports the goals and ideals of National 

4 Purple Heart Recognition Day; 

5 (2) encourages all people of the United States 

6 to learn about the history of the Purple Heart and 

7 to honor its recipients; and 

8 (3) requests that the President issue a procla9 mation calling on the people of the United States to 

10 conduct appropriate ceremonies, activities, and pro11 grams to demonstrate support for people who have 

12 been awarded the Purple Heart. 

Passed the Senate July 28, 2005. 

Attest: EMILY J. REYNOLDS, 

Secretary.
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2520 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2520

To suspend temporarily the duty on certain synthetic staple fibers that 
      are not carded, combed, or otherwise processed for spinning.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 29, 2009

  Mr. Graham introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To suspend temporarily the duty on certain synthetic staple fibers that 
      are not carded, combed, or otherwise processed for spinning.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ACRYLIC STAPLE FIBERS, COLORED AND CRIMPED.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00       Acrylic staple      Free         No change        No change        On or before 12/ ''.
                          fibers                                                             31/2011.......
                          (polyacrylonitril
                          e staple)
                          containing 85
                          percent or more
                          by weight of
                          acrylonitrile
                          units and 2
                          percent or more
                          but not over 3
                          percent of water,
                          colored, crimped,
                          with an average
                          filament decitex
                          of 2.2 (plus or
                          minus 10 percent)
                          and fiber length
                          of 45 mm (plus or
                          minus 10 percent)
                          (provided for in
                          subheading
                          5503.30.00)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
<PAGE>

EXHIBIT 32.1



                     CERTIFICATION PURSUANT TO:

                       18 U.S.C. SECTION 1350
                       AS ADOPTED PURSUANT TO
            SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Omagine, Inc. on Form
10-Q for the period ended March 31, 2010 (the "Report"), as
filed with the Securities and Exchange Commission on the date
hereof, the undersigned certifies, pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that:

        (1) The Report fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and

        (2) The information contained in the Report fairly
presents, in all material respects, the financial condition and
results of operations of Omagine, Inc.


/s/Frank J. Drohan
------------------
Frank J. Drohan
Chairman of the Board of Directors,
President and Chief Executive & Financial Officer
(Principal Executive Officer and Principal Financial Officer)


May 10, 2010

The originally executed copy of this certification will be
maintained at the Registrant's offices and will be made
available for inspection upon request.
No. 154.

#### Exhibit Supply Co. *v.*Ace Patents Corp.; Genco, Inc. *v.*Ace Patents Corp.; and Chicago Coin Machine Co. *v.*Ace Patents Corp.

No. 155.

No. 156.

March 2, 1942.

Mr. Justice Roberts took no part in the consideration or decision of this application.

*Ante,*p. 126.
EXHIBIT
32.2




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002




In
connection with the Quarterly Report of Columbia Laboratories, Inc. (the
“Company”) on Form 10-Q for the period ended March 31, 2008 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, James
A. Meer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
2002, that to the best of my knowledge:




(1)
            The
      Report fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and




(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.








/s/
James A. Meer


James A.
Meer


Chief
Financial Officer


May 9,
2008
#### Baldwin v. Century Care Ctr., Inc.

Case below: 180 N.C. App. 475

No. 626P06

1. Pit’s Motion for Temporary Stay (COA06-380)

2. Pit’s Petition for Writ of Supersedeas

3. Pit’s PDR Under N.C.G.S. § 7A-31

1. Denied 01/09/07

2. Denied 06/27/07

3. Denied 06/27/07